Evidence map›Paper›PMID 31177922›Full record

ArticleTechnology in cancer research & treatment

Can the Student Outperform the Master? A Plan Comparison Between Pinnacle Auto-Planning and Eclipse knowledge-Based RapidPlan Following a Prostate-Bed Plan Competition.

April Smith, Andrew Granatowicz, Cole Stoltenberg, Shuo Wang, Xiaoying Liang, Charles A Enke, Andrew O Wahl, Sumin Zhou, Dandan Zheng

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Artificial Intelligence in Radiation Therapy.IEEE transactions on radiation and plasma medical sciences · 2022
    Article
  7. Knowledge-based radiation treatment planning: A data-driven method survey.Journal of applied clinical medical physics · 2021
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

April Smith1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Andrew Granatowicz1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Cole Stoltenberg1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Shuo Wang1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Xiaoying Liang2 University of Florida Proton Therapy Institute, Jacksonville, FL, USA.
Charles A Enke1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Andrew O Wahl1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Sumin Zhou1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Dandan Zheng1 Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0003-2259-1633
University of Nebraska Medical Center · USUniversity of Florida Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePinnacle Auto-Planning and Eclipse RapidPlan are 2 major commercial automated planning engines that are fundamentally different: Auto-Planning mimics real planners in the iterative optimization, while RapidPlan generates static dose objectives from estimations predicted based on a prior knowledge base. This study objectively compared their performances on intensity-modulated radiotherapy planning for prostate fossa and lymphatics adopting the plan quality metric used in the 2011 American Association of Medical Dosimetrists Plan Challenge.

methodsAll plans used an identical intensity-modulated radiotherapy beam setup and a simultaneous integrated boost prescription (68 Gy/56 Gy to prostate fossa/lymphatics). Auto-Planning was used to retrospectively plan on 20 patients, which were subsequently employed as the library to build an RapidPlan model. To compare the 2 engines' performances, a test set including 10 patients and the Plan Challenge patient was planned by both Auto-Planning (master) and RapidPlan (student) without manual intervention except for a common dose normalization and evaluated using the plan quality metric that included 14 quantitative submetrics ranging over target coverage, spillage, and organ at risk doses. Plan quality metric scores were compared between the Auto-Planning and RapidPlan plans using the Mann-Whitney U test.

resultsThere was no significant difference between the overall performance of the 2 engines on the 11 test cases ( P = .509). Among the 14 submetrics, Auto-Planning and RapidPlan showed no significant difference on most submetrics except for 2. On the Plan Challenge case, Auto-Planning scored 129.9 and RapidPlan scored 130.3 out of 150, as compared with the average score of 116.9 ± 16.4 (range: 58.2-142.5) among the 125 Plan Challenge participants.

conclusionUsing an innovative study design, an objective comparison has been conducted between 2 major commercial automated inverse planning engines. The 2 engines performed comparably with each other and both yielded plans at par with average human planners. Using a constant-performing planner (Auto-Planning) to train and to compare, RapidPlan was found to yield plans no better than but as good as its library plans.

Indexed as

Knowledge BasesRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedAutomationHumansMaleProstatic NeoplasmsRadiometryRadiotherapy, Image-GuidedWorkflowautomationAuto-PlanKBPRapidPlantreatment planning

Identifiers

PMID31177922
PMCPMC6558545
OpenAlexW2949957602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.